BridgeBio Oncology Therapeutics Inc. (BBOT) vs Sagimet Biosciences Inc. (SGMT)
A side-by-side comparison of BridgeBio Oncology Therapeutics Inc. and Sagimet Biosciences Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BBOT
BridgeBio Oncology Therapeutics Inc.
$3.53HealthcareDelayed quote: Oct 6, 2026, 2:00 PM EDT
SGMT
Sagimet Biosciences Inc.
$8.77HealthcareDelayed quote: Oct 6, 2026, 1:55 PM EDT
Total return — BBOT vs SGMT
growth of $100 · dividends reinvested · last 3yBBOT -64.7% (-29.3%/yr)SGMT +44.7% (+13.1%/yr)SGMT compounded faster over this window
BBOT SGMT
BBOT vs SGMT: by the numbers
- •SGMT is the larger company ($286M vs $283M market cap).
Metrics side by side
Valuation
| Metric | BBOT | SGMT |
|---|---|---|
| P/B ratio | 0.88 | 1.12 |
Profitability
| Metric | BBOT | SGMT |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -56.36% | -18.38% |
| ROIC | -61.10% | -20.40% |
Go deeper
Dig into the metrics
BridgeBio Oncology Therapeutics ROESagimet Biosciences ROEBridgeBio Oncology Therapeutics operating marginSagimet Biosciences operating marginBridgeBio Oncology Therapeutics revenue growthSagimet Biosciences revenue growthBridgeBio Oncology Therapeutics free cash flowSagimet Biosciences free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.